|
1
|
Müller AM, Ihorst G, Mertelsmann R and
Engelhardt M: Epidemiology of non-Hodgkin's lymphoma (NHL): Trends,
geographic distribution, and etiology. Ann Hematol. 84:1–12. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Basharat S, Iqtidar BH, Naeem S, Batool Z,
Ali N and Ahmad Z: Clinicopathological and immunohistochemical
profile of patients with Non-hodgkin's lymphoma. RMJ. 44:472–476.
2019.
|
|
3
|
Iyer VK: Pediatric lymphoma diagnosis:
Role of FNAC, biopsy, immunohistochemistry and molecular
diagnostics. Indian J Pediatr. 80:756–763. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Binder M, O'Byrne MM, Maurer MJ, Ansell S,
Feldman AL, Cerhan J, Novak A, Porrata LF, Markovic S, Link BK and
Witzig TE: Associations between elevated pre-treatment serum
cytokines and peripheral blood cellular markers of
immunosuppression in patients with lymphoma. Am J Hematol.
92:752–758. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ansell SM and Armitage J: Non-Hodgkin
lymphoma: Diagnosis and treatment. Mayo Clin Proc. 80:1087–1097.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Küçükzeybek BB, Bener S, Çallı AO, Paksoy
TD and Payzin B: Prognostic significance of Bcl-2 and p53 protein
expressions and Ki67 proliferative index in diffuse large B-cell
lymphoma. Turk J Haematol. 30:275–282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fayad L, Keating MJ, Reuben JM, O'Brien S,
Lee BN, Lerner S and Kurzrock R: Interleukin-6 and interleukin-10
levels in chronic lymphocytic leukemia: Correlation with phenotypic
characteristics and outcome. Blood. 97:256–263. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng G, Servaes S, Alavi A and Zhuang H:
FDG PET and PET/CT in the management of pediatric lymphoma
patients. PET Clin. 3:621–634. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Watabe T, Tatsumi M, Watabe H, Isohashi K,
Kato H, Yanagawa M, Shimosegawa E and Hatazawa J: Intratumoral
heterogeneity of F-18 FDG uptake differentiates between
gastrointestinal stromal tumors and abdominal malignant lymphomas
on PET/CT. Ann Nucl Med. 26:222–227. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Novelli S, Briones J, Flotats A and Sierra
J: PET/CT Assessment of follicular lymphoma and high Grade B cell
lymphoma-good correlation with clinical and histological features
at diagnosis. Adv Clin Exp Med. 24:325–330. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Berghmans T, Dusart M, Paesmans M,
Hossein-Foucher C, Buvat I, Castaigne C, Scherpereel A, Mascaux C,
Moreau M, Roelandts M, et al: Primary tumor standardized uptake
value (SUVmax) measured on fluorodeoxyglucose positron emission
tomography (FDG-PET) is of prognostic value for survival in
non-small cell lung cancer (NSCLC): A systematic review and
meta-analysis (MA) by the European lung cancer working party for
the IASLC lung cancer staging project. J Thorac Oncol. 3:6–12.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Diao W, Tian F and Jia Z: The prognostic
value of SUV (max) measuring on primary lesion and ALN by (18)
F-FDG PET or PET/CT in patients with breast cancer. Eur J Radiol.
105:1–7. 2018. View Article : Google Scholar : PubMed/NCBIPubMed/NCBI
|
|
13
|
Hu SL, Yang ZY, Zhou ZR, Yu XJ, Ping B and
Zhang YJ: Role of SUV(max) obtained by 18F-FDG PET/CT in patients
with a solitary pancreatic lesion: Predicting malignant potential
and proliferation. Nucl Med Commun. 34:533–539. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tokuda E, Horimoto Y, Arakawa A, Himuro T,
Senuma K, Nakai K and Saito M: Differences in Ki67 expressions
between pre- and post-neoadjuvant chemotherapy specimens might
predict early recurrence of breast cancer. Hum Pathol. 63:40–45.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gaudio F, Giordano A, Perrone T, Pastore
D, Curci P, Delia M, Napoli A, de Risi C, Spina A, Ricco R, et al:
High Ki67 index and bulky disease remain significant adverse
prognostic factors in patients with diffuse large B cell lymphoma
before and after the introduction of rituximab. Acta Haematol.
126:44–51. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Uzurov-Dinić V, Savic A, Lazarević T,
Cemerikić-Martinović V, Agić D and Popović S: Prognostic factors in
patients with diffuse large B-cell lymphoma. Med Pregl. 62:171–176.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Swerdlow SH: WHO Classification of Tumours
of Haematopoietic and Lymphoid. 2008.
|
|
18
|
International Non-Hodgkin's Lymphoma
Prognostic Factors Project: A predictive model for aggressive
Non-Hodgkin's-Lymphoma. N Engl J Med. 329:987–994. 1993.
|
|
19
|
Carbone PP, Kaplan HS, Musshoff K,
Smithers DW and Tubiana M: Report of the Committee on Hodgkin's
disease staging classification. Cancer Res. 31:1860–1861.
1971.PubMed/NCBI
|
|
20
|
Juweid ME, Stroobants S, Hoekstra OS,
Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L,
Scheidhauer K, Buck A, et al: Use of positron emission tomography
for response assessment of lymphoma: Consensus of the Imaging
Subcommittee of International Harmonization Project in Lymphoma. J
Clin Oncol. 25:571–578. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gigliotti E: Discovering statistics using
SPSS, Second edition. JAN. 58:3032007. View Article : Google Scholar
|
|
22
|
Lee H, Kim SK, Kim YI, Kim TS, Kang SH,
Park WS, Yun T and Eom HS: Early determination of prognosis by
interim 3′-deoxy-3′-18F-fluorothymidine PET in patients with
non-Hodgkin lymphoma. J Nucl Med. 55:216–222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ying Z, Wang X, Song Y, Zheng W, Wang X,
Xie Y, Lin N, Tu M, Ping L, Liu W, et al: Prognostic value of
interim (18)F-FDG PET/CT in diffuse large B-cell lymphoma. Chin J
Cancer Res. 25:95–101. 2013.PubMed/NCBI
|
|
24
|
Wen SY, Hua JZ, Li QW, Yan X, Xiang C and
Jian-Hua S: Prognostic significance of interim F-18-F-FDG PET/CT
SUV reduction associated with Ki67 in patients with diffuse large
B-cell lymphoma. Nuclear Sci Techniques. 25:1–7, 2014. 2014.
|
|
25
|
Casasnovas RO, Meignan M,
Berriolo-Riedinger A, Bardet S, Julian A, Thieblemont C, Vera P,
Bologna S, Brière J, Jais JP, et al: SUVmax reduction improves
early prognosis value of interim positron emission tomography scans
in diffuse large B-cell lymphoma. Blood. 118:37–43. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tang B, Malysz J, Douglas-Nikitin V,
Zekman R, Wong RH, Jaiyesimi I and Wong CY: Correlating metabolic
activity with cellular proliferation in follicular lymphomas. Mol
Imaging Biol. 11:296–302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Scholzen T and Gerdes J: The Ki-67
protein: From the known and the unknown. J Cell Physiol.
182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pătraşcu AM, Rotaru I, Olar I, Pătraşcu Ş,
Ghiluşi MC, NeamŢu SD, Nacea JG and Gluhovschi A: The prognostic
role of Bcl-2, Ki67, c-MYC and p53 in diffuse large B-cell
lymphoma. Rom J Morphol Embryol. 58:8372017.PubMed/NCBI
|
|
29
|
Albano D, Bertoli M, Ferro P, Fallanca F,
Gianolli L, Picchio M, Giubbini R and Bertagna F: 18F-FDG PET/CT in
gastric MALT lymphoma: A bicentric experience. Eur J Nucl Med Mol
Imaging. 44:589–597. 2017. View Article : Google Scholar : PubMed/NCBI
|
